Cargando…
Cost Analysis of Aprotinin Reintroduction in French Cardiac Surgery Centres: A Real-World Data-Based Analysis
INTRODUCTION: The European Medicines Agency restored aprotinin (APR) use for preventing blood loss in patients undergoing isolated coronary artery bypass graft (iCABG) in 2016 but requested the collection of patient and surgery data in a registry (NAPaR). The aim of this analysis was to evaluate the...
Autores principales: | Colson, Pascal, Fellahi, Jean-Luc, Gaudard, Philippe, Provenchère, Sophie, Rozec, Bertrand |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070296/ https://www.ncbi.nlm.nih.gov/pubmed/36867329 http://dx.doi.org/10.1007/s12325-023-02464-7 |
Ejemplares similares
-
Anti-tumour Activity of Aprotinin
por: Latner, A. L., et al.
Publicado: (1974) -
Antifibrinolytic Agents: Aprotinin, and Desmopressin
por: Bajaj, Pramila
Publicado: (2009) -
Identification of an aprotinin antiviral domain
por: Pellegrini, Antonio, et al.
Publicado: (1994) -
Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis
por: Schulz, Martin S., et al.
Publicado: (2022) -
Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction
por: Normatov, Inessa, et al.
Publicado: (2021)